Inflammatory activity during multiple sclerosis (MS) often improves during pregnancy, suggesting that pregnancy-related immune adaptations affect the disease. Here we show that growth/differentiation factor-15 (GDF-15) increases during pregnancy and correlates with a reduced rate of MS relapses. GDF-15 also accumulates in the inflamed central nervous system, and its absence impairs inflammation resolution in a mouse model of MS. GDF-15 suppresses autoimmune T cell responses through an indirect signaling pathway involving the activation of GDNF family receptor α-like (GFRAL) on brainstem neurons. Therapeutic approaches, including neuronal gene delivery, recombinant GDF-15 administration and targeted chemogenetic activation of GFRAL-positive neurons induce β-adrenergic signaling and norepinephrine synthesis in the spleen, leading to decreased expression of integrins on T cells required for transmigration across the blood-brain barrier and confer protection against neuroinflammation in preclinical models of MS. These findings position GDF-15 as a crucial neuroimmune mediator and the GDF-15-GFRAL axis as promising target for MS.
https://doi.org/10.1038/s41590-025-02406-1
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HV986016 | Anti-Human GDF-15 Reference Antibody (Ponsegromab | Ponsegromab (HV986016) is a research-grade recombinant antibody targeting PLAB. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. | PLAB, Placental bone morphogenetic protein, MIC1, NRG-1, PTGFB, NSAID-regulated gene 1 protein, GDF15, NAG-1, MIC-1, Prostate differentiation factor, NSAID-activated gene 1 protein, Growth/differentiation factor 15, Macrophage inhibitory cytokine 1, Placental TGF-beta, GDF-15, PDF |

24小时产品查询

扫一扫关注我们

专属渠道经理